S. Gentile, A. De Bartolomeis, G. Muscettola - Vol. 6, Marzo 2000, num.1
Testo Immagini Bibliografia Summary Riassunto Indice
Farmaci psicotropi di II generazione: possibilitŕ e limiti
di utilizzo in gravidanza e allattamento
The "new" psychotropic drugs: their use in pregnancy and lactation
1 Bellantuono C, Tansella M.
Gli psicofarmaci nella pratica terapeutica.
III ed. Roma: Il Pensiero Scientifico 1994:533-545.
2 Farrar HC, Blumer JL.
Fetal effects of maternal drug exposure.
Annual Review of Pharmacoogy and Toxicology 1991;31:525-547.
3 Knott C, Reynolds F.
Therapeutic drug monitoring in pregnancy. Rationale and current status.
Clinical Pharmacokinetics 1990;19:425-433.
4 Robinson GE, Stewart DE, Flack E.
The rationale use of psychotropic drugs in pregnancy and postpartum.
Canadian Journal of Psychiatry 1986;31:183-190.
5 Mortola JF.
The use of psychotropic agents in pregnancy and lactation.
Psychatric Clinics of North America 1989;12:69-87.
6 Atkinson HC, Begg EJ.
Prediction of drug distribution into human milk from physicochemical characteristics.
Clinical Pharmacokinetics 1990;18:151-167.
7 American Academy of Pediatrics Committee on Drugs.
The transfer of drugs and other chemicals into human milk.
Pediatrics 1994;93:137-150.
8 Llewellin A, Stowe NZ.
Psychotropic medications in lactation.
Journal of Clinical Psychiatry 1998;59(suppl.2):41-52.
9 Pons G, Rey W, Matherson I.
Excretion of psychoactive drugs into breast milk.
Clinical PharmacoKinetics in Special Populations 1994;27:270-289.
10 Kacew S.
Adrerse effects of drugs and chemicals in brenst milk on the nursing infant.
Journal of Clinical Pharmacology 1993;33:213-220.
11 Mortola JF.
The use of psychotropic agents in pregnancy and lactation.
Women’s Disorders 1989;12:69-87.
12 Buist A, Norman TR, Dennerstein L.
Breastfaeding and the use of psychotropic medication. A review.
Journal of Affective Disorders 1990;19:197-206.
13 Stowe ZN, Owens MJ, Landry JC, e Coll.
Sertraline and desmethilsertraline in human breast milk and nursing infant.
American Journal of Psychiatry 1997;15:1255-1260.
14 Atkinson HG, Begg EJ, Darlow BA.
Drugs in human milk: clinical pharmacolinetic considerations.
Clinical Pharmacokinetics 1988;14:217-240.
15 Morselli PL, Franco-Morselli R, Bossi L.
Clinical pharmacolinetics in newborn and infants: age related differences
and therapeutic implications.
Clinical Pharmacokinetics 1980;5:485-527.
16 O’Dea RF.
Medication use in fhe breastfaeding mother.
NAACOG Clinical Issue in Perinatal and Women’s Health Nursing 1992;3:598-604.
17 Cohen L, Rosembaum JF.
Psychotropic drugs use during pregnancy: Weighting the Risk.
Journal of Clinical Psychiatry 1998;59(suppl.2):18-28.
18 Doering JC, Stewart RB.
The extent and character of drug consumption during pregnancy.
JAMA 1978;239:843-846.
19 O’Hara MW.
Postpartum mental disorders.
In: Sciarra JJ, ed. Ginecology and Obstetrics. Philadelphia: Harper
& Row 1991.
20 O’Hara MW, Schelechte JA, Lewis DA, e Coll.
Prospective study of postpartum blues. Biologic and psychosocial factors.
Archives of General Psychiatry 1991;48:801-806.
21 Kendall RE, Chalmes JC, Platz C.
Epidemiology of puerperal psychosis.
British Journal of Psychiatry 150: 662-673.
22 Davidson J, Robertson E.
A follow-up study of postpartum illness, 1946-1978.
Acta Psychiatrica Scandinavica 1985;71:451-457.
23 Platz A, Kendall RE.
A matched-control follow-up study and family study of "puerperal psychosis".
British Journal of Psychiatry 1988;153:90-94.
24 Ruta N, Lee SC.
Postpartum mood disorders: Diagnosis and treatment guidelines.
Journal of Clinical Psychiatry 1998;59(suppl.2):30-40.
25 Kumar R, Robson KM.
A prospective study of emotional disorders in chilbearing women.
British Journal of Psychiatry 1984;144:35-47.
26 Cox JL, Connor Y, Kendall RE.
Prospective study of the psychiatric disorders in childbirth.
British Journal of Psychiatry 1982;140:111-117.
27 Keller MB, Lavori PW, Muller TI, e Coll.
Time to recovery, chronicity and levels of psychopathology in major depression:
A five-years follow-up of 431 subjiects.
Archives of General Psychiatry 1992;49:809-816.
28 Weimberg MK, Tronick EL.
Maternal depression and infant maladjustment: A failure of mutual regulation.
In: Noshpitz JD, ed. Handbook of Child and Adolscent Psychiatry. New
York, NY: John Wiley & Sons 1997.
29 Cummings EM, Davies PT.
Maternal depression and child development.
Journal of Child Psychology and Psychiatry and Allied Disciplines 1994;35:73-112.
30 Godman SH.
Understading the effects of depressed mothers on their children.
Prog Exp Personality Psychopathol Res 1992;15:47-104.
31 Pohland RC, Byzol TC, Hamilton M, e Coll.
Placental transfer and fetal distribution of fluoxetine in the rat.
Toxicology and Applied Pharmacology 1989;98:l,98205.
32 Shuey DL, Sadler TW, Lauder JM.
Serotonine as a regulator of craniofacial morphogenesis: Site-specific
malformation following exposure to serotonine uptake inhibitors.
Teratology 1992;46:367-378.
33 Nulman I, Koren G.
The safety of Fluoxetine during pregnancy and laclation.
Teratology 1996;53:304-308.
34 Goldstein DJ.
Outcome of fluoxetine-exposed pregnancies.
American Journal of Human Genetics 1990;47:A136.
35 Goldstein DJ, Williams ML, Peason DK.
Fluoxetine-exposed pregnancies.
Clin Res 1991;39:76-80.
36 Chambers C, Johnson K, Jones K.
Pregnancy outcome in women exposed to fluoxetine.
Teratology 1993;47:386.
37 Pastuszac A, Boschetto BS, Zuber C, e Coll.
Pregnancy outcome following first-trimester exposure to Fluoxetine (Prozac).
JAMA 1993;17:2246-2248.
38 Nulman I, Rovet J, Stewart D, e Coll.
Neurodevelopment of children exposed in utero to antidepressant drugs.
New England Journal of Medicine 1997;336:258-262.
39 Goldstein D, Corbin L, Sundell K.
Effects of first-trimester fluoxetine exposure in the newborn.
10° European College Neuropsychopharmacology, Abstracts, Wien 1997.
40 Burch JJ, Wells BG.
Fluoxetine/Norfluoxetine concentrations in human milk.
Journal of Pedriatrics 1992;89:676-677.
41 Isemberg KE.
Excretion of fluoxetine in human breast milk.
Journal of Clinical Psychiatry 1990;51:169.
42 Lester BM, Cucca J, Andreozzi L, e Coll.
Possible association between fluoxetine hydrochloride and colic in an infant.
Am Acad Child Adoles Psychiatry 1993;32:1253-1255.
43 Taddio A, Ito S, Koren G.
Excretion of fluoxetine and its metabolite in human breast milk.
Pediatric Research 1994;35:1A-443A.
44 Luvox [package insert], Scarborongh, Ontario: Solvay Kingswood 1991.
45 Paxil [package insert], Mississauga, Ontario: SmithKline Beecham Pharmaceuticals
1995.
46 Zoloft [package insert], Kirkland, Quebec: Pzifer Pharmaceuticals 1994.
47 Kulin NA, Pastuszak A, Sage SR, e Coll.
Pregnancy outcome following maternal use of the new Selective Serotonin
Reuptake Inhibitors.
JAMA 1998;.279:609-610.
48 Mammen OK, Perel JM, Rudolph G, e Coll.
Sertraline and norsertraline levels in three breastfed infants.
Journal of Clinical Psychiatry 1997;58:100-103.
49 Stowe ZN, Owens MI, Landry JC, e Coll.
Sertraline and desmethylsertraline in human breast milk and nursing infant.
American Journal of Psychiatry 1997;154:1255-1260.
50 Wright S, Dawling S, Ashford JJ.
Excretion of fluoxamine in breast milk (letter).
British Journal of Clinical Pharmacology 1991;31:209.
51 Spigset O, Carleborg L, Norstrom A, e Coll.
Paroxetine level in breast milk (letter).
Journal of Clinical Psychiatry 1996;57:n.39.
52 Lundbeck Italia SpA: Data on file. Investigator’s brochure.
53 Seifritz E, Trachsler EH, Haberthur F, Hemmeter U, Poldin ger W.
Unrecognized pregnancy during Citalopram treatment. (letter).
American Journal of Psychiatry 1993;9:150-?.
54 Spigset O, Carleborg L, Ohman R, Norstrom A.
Excretion of citalopram in breast milk.
British Journal of Pharmacology 1997;44:295-298.
55 Jensen NP, Olesen OV, Bartelsen A, Linnet K.
Citalopram and desmethilcitalopram concentrations in breast milk and in
serum of mother and infant.
Therapeutic Drug Monitoring 1997;19:236-239.
56 Bauman P, Rochat B.
Comparative pharmacokinetics of selective serotonin reuptake inhibitors:
a look behind the mirror.
International Clinical Psychopharmacology 1995;10:15-21.
57 Bracco Spa: Data on file 1: Investgator’s brochure.
58 Fed Register June 26, 1979;44(124):37404.
59 Data on file, Wyeth-Ayerst Laboratories.
60 Data on file (spontaneous adverse experience reporting system), Wyeth-Ayerst
Laboratories.
61 Product information, Remeron. Organon 1997.
62 Simhandl C, Zhoglami A, Pinder R.
Pregnancy during use of mirtazapine.
11th European Congress Psychoneuropharmacology, Paris, France: Abstract
1998;P.1.038.
63 Briggs GG, Freeman RK, Yaffe SJ.
Drugs in pregnancy and lactation. A reference guide to fetal and neonatal
risk. Fifth edition. Williams & Wilkins eds, Baltimore 1998;739/m.
64 Product information. Serzone. Bristol-Myers Squibb, 1996.
65 Miller AA, Sawyer DA, Roth B, e Coll.
Lamotrigine.
In: Meldrum BS, Porter RJ, eds. New anticonvulsivant drugs. London:
John Libby 1986:165-177.
66 Miller AA, Wheatley PL, Sawyer DA, Baxter MG, Roth B.
Pharmacolocical studies on lamotrigine, a novel potential antiepileptic
drug: I. Anticonvalsivant profile in mice and rats.
Epilepsy 1986;27:483-489.
67 Tennis P, Elridge RR.
Interim results of the lamotrigine pregnancy registry.
Glaxo Wellcome Co., RPT, NC, USA & the Lamotrigine Registry Advisory
Commitee. Lamictal Poster presented at the 22nd International Epilepsy Congress:
Dublin, Ireland: 29th June-4th July, 1997.
68 Rambeck B, Kurlemann G, Stodieck SRG, May TW, Jurgens U.
Concentrations of lamotrigine in a mother on lamotrigine treatment and
her newborn child.
European Journal of Clinical Pharmacology 1997;51:481-484.
69 Nau H, Kuhnz W, Egger HJ, Rating D, Helge H.
Anticonvulsivants during pregnancy and lactation. Transplacental, maternal
and neonatal pharmacolinetics.
Clinical Pharmacokinetics 1982;7:508-543.
70 Kaneko S, Sato F, Suzuki K.
The levels of anticonvulsivants in breast milk.
Bitishr Journal of Clinical Pharmacology 1979;7:624-627.
71 Dichter MA, Brodie MJ.
New antiepileptic drugs.
New England Journal of Medicine 1996;334:1583-1590.
72 Product information. Neurontin. Parke-Davis, 1997.
73 Rosa F.
Holoprosencephaly and antiepileptic exposures.
Teratology 1995;51:230.
74 Lamotrigine Pregnancy Registry. Interim Report. 1 September 1992 through
30 September 1996. Glaxo Wellcome Inc., 1997.
75 Kay S, Kohmura H, Ishikawa K, e Coll.
Reproductive and developmental toxicity studies of buspirone hydrocloryde
(I- II): Oral administration to rats during the period of fetal organogenesis.
Journal of Toxicology Sciences 1990;15(suppl.l):31-84.
76 Kim JA, Gillespie RA, Druse MJ.
Effects of maternal ethanol consumption and buspirone treatment on 5-HT
(IA) and 5-HT (2A) receptors in offspring.
Alcoholism, Clinical and Experimental Research MedA 1997;21:1169-1178.
77 Tajuddin NF, Druse MJ.
Treatment of pregnant alcohel-consuming rats with buspirone: Effeols on
serotonin and 5-hydroxyindoleocetic acid content in offspring.
Alcoholism, Clinical and Experimental Research MedA 1993;17:110-114.
78 Eriksen JL, Gillespie RA, Simmons WH, Druse-Manteuffel MJ.
Effects of maternal ethanol consumption and buspirone treatment on dopamine
and norepinephrine reuptake sites in offspring.
Abstr Soc Neurosci 1996:22(P3).
79 Fiedman CJ, Prenez A.
Safety evaluation of Zolpidem.
In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep
Disorders. New York: Raven Press 1988.
80 Pons G, Francoual C, Guillet Ph, e Coll.
Zolpidem excretion in breast milk.
European Journal of Clinical Pharmacology 1989;37:245-248.
81 Spigset O, Hagg S.
Excretion of psychotropic drugs into breast milk. Pharmacolinetic overview
and therapeutic implications.
CNS Drugs 1998;9(2):111-134.
83 Data on file, Lilly Research Laboratories, Ely Lilly and Company.
84 Dickson RA, Dawson DT.
Olanzapine and pregnancy.
Canadian Journal of Psichiatry 1998;43:196-197.
85 Tolis G, Friesen HG.
Prolactin and human reproduction.
Can Med Assoc J 1976;115:709-711.
86 Kaplan B, Modai I, Stoler M, Kitai E, Valevski A, Weizman A.
Clozapine treatment and risk of unplanned pregnancy.
J Am Board Fam Pract 1995;8:239-241.
87 Lieberman J, Safferman AZ.
Clinical profile of clozapine: adverse reoctions and agranulocytosis.
In: Jones LY, ed. Clozapine in treatment resistant schizophrenia: a
scientific update. London: Royal Society of Medicine 1992.
88 Waldman MD, Safferman AZ.
Pregnancy and clozapine (letter).
American Journal of Psychiatry 1993;150:168-169.
89 Dev V, Krupp P.
The side-effects and safety of clozapine.
Rev Contemp Pharmacother 1995;6:197-208.
90 Tényi T, Trixler M.
Clozapine in the treatment of pregnant schizophrenic women.
Psychiatria Danubina. In press.
91 Barnas C, Bergant A, Hummer M, e Coll.
Clozapine concentrations in maternal and fetal plasma, amniotic fluid,
and breastmilk (letter; comment).
American Journal of Psychiatry 1994;151:945.
92 Van Cauteren H, Megens AAHP, Lampo A, Meuldermans W.
Risperidone: an overview of animal pharmacology, toxicology and pharmacolinetics.
In: Kane MJ, Moller HJ, Awouters F, eds. Serotonin in antipsychotic
treatment. Mechanism and clinical practice. New York, Basel, Hong Kong:
Marcel Dekker Inc. 1996:235-276.
93 Reyilly TM, Heylen SLE.
Guidelines for the practical use of risperidone.
I n: Kane MJ, Moller HJ, Awouters F, eds. Serotonin in anti psychotic
treatment. Mechanism and clinical practice. New York, Basel, Hong Kong:
Marcel Dekker Inc. 1996:357-368.
94 Woestenborghs R, Lorreyne W, Van Rompaey F, Heykants J.
Determination of risperidone and 9-hydroxy-risperidone in plasma, urine
and animal tissues by high-performance liquid chromatography.
Journal of Chromatographic Science 1992;583:223-230.
94 Pregnancy categories for prescription drugs.
FDA Drug Bull 1982;12:2425.
95 Batagol R, ed.
Drugs in pregnancy.
The Royal Women’s Hospital, CSL Limited, Victoria, Australia 1993.
96 Bundesverband der Pharmazeutischen Industrie e. V. Arzneimittel in Schwangers
und Stillzeit; ROTE LISTE® 1997;Seite313-315.
97 Beck AT, Rush AJ, Shaw BF.
Cognitive therapy of depression.
New York: Guilford 1979.
98 Klerman GL, Weissman MM, Rounsaville BJ, e Coll.
Interpersonal psychotherapy of depression.
Ed. New York City: Basic Books, Inc., Publishers 1984.
99 Cohen LS.
Pharmacologic treatment of depression in women: PMS, pregnancy, and the
postpartum period.
Depression Anxiety 1988;8(suppl.1):18-26.
100 Repke JT, Berger NG.
Electrocnvulsive therapy in pregnancy.
Obstetrics and Gynecology 1984;63:392-412.
101 Sobel DE.
Fetal damage due to ECT, insulin coma, chlorpromazine or reserpine.
Archives of General Psychiatry 1960;2:606-611.
102 Lam RW, Kripke DF, Gillin JC.
Phototherapy for depressive disorders: a review.
Canadian Journal of Psychiatry 1989;34:140-147.
103 Wu JC, Bunney WE.
The biologic basis of antidepressant response to sleep deprivation and
relapse.
Am J Psychiatry 1990;147:14-21.
104 Trixler M, Tenyi T.
Antipsychotic use in pregnancy. What are the best treatment options?
Drug Safety Concepts 1997;16:403-410.
105 Wrede G, Mednick SA, Hottunen MO, e Coll.
Pregnancy and delivery complications in the births of an unselected series
of Finnish children with schizophrenic mothers.
Acta Psychiatrica Scandinavia 1980;62:369-381.
106 Mille IJ.
Psychotic denial of pregnancy: phenomenology and clinical management.
Hosp Community Psychiatry 1990;41:1233-1237.
107 Altshuler LL, Cohen L, Szuba MP, e Coll.
Pharmacologic management of psychiatric illness during pregnancy: dilemmas
and guidelines.
American Journal of Psychiatry 1996;153:592-606.
108 Trixler M, Gŕti A, Tényi T.
Risis associated with childbearing in schizophrenia.
Acta Psychiatrica Belgica 1995;95:159-162.
109 Weisler RH, Risner ME, Ascher JA, Houser TL.
Use of lamotrigine in the treatment of bipolar disorder.
APA New Research Program and Abstracts, Abstract 1994:#NR611:206.
110 Calabrese JR, Bowden CL, Rhodes LJ, e Coll.
Lamotrigine in treatment-refractory bipolar disorder [Abstract].
Abstracts of the 149th Annual Meeting, American Psychiatric Association, Abstract
1996;36:15.
111 Post MR, Ketter TA, Denicoff K, e Coll.
The place of anticonvulsivant therapy in bipolar illness.
Psychopharmacology 1996;128:115-129.